Selenomethionine
Phase 2Small molecule
Selenomethionine is one of 45 small molecule programs targeting Pembrolizumab. It is currently in Phase 2.
1
Indications
3
Total Trials
1
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
51 competitors in Pembrolizumab
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Stivarga
BayerPhase 3
Lenvima
EisaiPhase 2
Taxol
TevaPhase 2
Paraplatin
AAvyxa
Phase 2
Cyramza
Eli LillyPhase 2
Trodelvy
GileadPhase 2
Lynparza
AstraZenecaPhase 2
Rituxan
RochePhase 2
Istodax
TevaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Selenomethionine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MMohammed Milhem